MARIETTA, Ga., March 17, 2016 /PRNewswire/ -- Vivex Biomedical, Inc., a leading processor of human tissue, synthetics, mimetic patterning technology, and biocellular products, announced today that its subsidiary, UMTB Biomedical, Inc., hired Dave Fronk as Vice President of Quality Systems and promoted Dr. Shabnam Namin to Vice President of Research and Development. Vivex Biomedical formed UMTB Biomedical as a wholly-owned subsidiary to acquire the University of Miami Tissue Bank (UMTB) in November 2014. UMTB is the oldest tissue bank in the country.
David M. Fronk joined UMTB Biomedical, Inc. in December 2015, as Vice President of Quality Systems. Dave has 30 years of experience within the medical device industry, including 23 years of experience in the tissue banking industry. Prior to joining UMTB Biomedical, he held Regulatory, Quality, and Clinical Research executive management positions at CryoLife, Inc., a leading processor of cardiovascular human tissue and medical device manufacturer located in Atlanta, Georgia. Previous to this, he held various orthopaedic product development positions at Baxter Healthcare Corporation and Zimmer, Inc. He received both his B.S. in mechanical engineering and his M.S. in biomedical engineering from the Ohio State University.
Dr. Shabnam Namin joined UMTB three years ago and has successfully and progressively led the Research and Development team at UMTB Biomedical, most recently launching four new products and five new line extensions. She has been responsible for leading product development of all cell and tissue based product for the company. In addition, Dr. Namin is an important member of the commercialization team with a main interest in the development of regenerative therapies. Prior to joining UMTB, Dr. Namin earned her PhD in Biomedical Engineering from Florida International University. She also received an MBA and MS in Industrial Engineering from the University of Miami. During her studies, Dr. Namin spent several years working in many different facets in the tissue engineering realm, focusing on the commercialization of cell and tissue based products. She has multiple publications and patents for her work on the development of these therapies. She is currently an active member of both the Birth Tissue Committee as well as the Scientific & Technical Affairs Committee (STAC) for the American Association of Tissue Banks.
"As we continue to strengthen the quality of our management team, we seek out the best and the brightest in the industry. Dave and Dr. Namin fit that bill perfectly. They are among the best in their respective fields and we are truly excited about the work that they have already begun to do to further our mission to be the premier biomedical company in the country," stated Tracy Anderson, President & CEO Vivex Biomedical, Inc.
"The caliber of Dave & Dr. Namin add significant capabilities to our team. Their skill sets complement those on our team and position Vivex Biomedical and UMTB Biomedical as an emerging leader in our industry," says Lou Barnes, President & COO UMTB Biomedical, Inc.
About Vivex Biomedical, Inc.: Vivex Biomedical is a privately held company based out of Marietta, Georgia focused on cellular therapies that treat orthopaedic, spine, wound and soft tissue indications. Vivex and its wholly owned subsidiary, UMTB Biomedical, Inc., own and hold exclusive rights to proprietary technologies in the field of biomedicine, stem cells, and orthopaedic implant surface modification. The Vivex Biomedical technology includes marrow isolated adult multilineage inducible (MIAMI) cell identification and processing, as well as, mimetic patterning technologies (MIME) which can improve the efficiency and efficacy of a patient's healing cascade and reduce the overall cost of healthcare.
About UMTB Biomedical, Inc.: Founded in 1970 through a partnership with the U.S. Naval Hospital in Bethesda, MD, the University of Miami Tissue Bank ("UMTB") is the oldest tissue bank in the United States. UMTB was acquired November of 2014 by UMTB Biomedical, Inc., a wholly owned subsidiary of Vivex Biomedical. UMTB has been led by H. Thomas Temple, M.D., a world renowned orthopaedic oncologist and surgeon.
Safe Harbor Statements. This press release contains forward-looking statements. These forward-looking statements are based on our current assumptions, expectations, and estimates of future events and trends. Forward-looking statements are only predictions and are subject to many risks, uncertainties, and other factors that may affect our businesses and operations and could cause actual results to differ materially from those predicted. These risks and uncertainties include, without limitation, factors affecting our financial results, demand for our products, our ability to obtain regulatory clearance or approval, where necessary, from the U.S. Food and Drug Administration, our ability to compete successfully, our ability to safeguard our intellectual property, and our ability to comply with laws and regulations that are or may become applicable to our businesses. Given these risks and uncertainties, readers are cautioned not to place undue reliance on any forward-looking statements.
SOURCE Vivex Biomedical, Inc.